Antineoplastic Agents

Alkylating Agents
1. Nitrogen Mustards
  1. Cyclophosphamide
    1. Acute & chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), breast, lung, and ovarian cancers
  2. Ifosfamide
    1. Sarcoma, testicular cancer
  3. Bendamustine
    1. CLL, NHL
    2. Used in combination with Rituxan
2. Nitrosoureas
  1. Carmustine
    1. Brain cancers
  2. Lomustine
    1. Brain cancers
3. Triazenes
  1. Dacarbazine
    1. Treats Hodgkin's lymphoma as part of ABVD
    2. Malignant melanomas
  2. Temozolomide
    1. Malignant gliomas (with radiation)
4. Platinum Analogs
  1. Cisplatin
    1. Testicular, ovarian, bladder, lung carcinomas
    2. Part of BEP
  2. Carbaplatin
    1. Ovarian cancer
  3. Oxaliplatin
    1. Gastric, colorectal cancer
    2. Part of FOLFOX
Antimetabolites
1. Folate Analogs
  1. Methotrexate
    1. Part of combo therapy for Burkitt's lymphoma, and breast, ovary, head and neck, and bladder carcinomas
    2. Childhood Acute Lymphoblastic Leukemia (ALL), choriocarcinoma, meningeal leukemia, and osteosarcoma
  2. Pemetrexed
    1. Colon, non-small cell lung, and pancreatic cancer, and mesothelioma
2. Pyrimidine Analogs
  1. 5-Fluorouracil (5-FU)
    1. Part of combo therapy for breast, colorectal, gastric, head and neck, cervical, and pancreatic cancer
    2. Basal cell carcinomas
  2. Capecitabine
    1. New oral form of 5-FU
    2. Metastatic breast cancer, colorectal cancer
  3. Cytarabine
    1. Acute myeloid leukemia (AML), ALL, and blast phase CML
  4. Gemcitabine
    1. Pancreatic, non-small cell lung cancer, ovarian, bladder, esophageal, and head and neck cancers
3. Purine Analogs
  1. 6-Mercaptopurine (6-MP)
    1. Maintaining remission in acute lymphoblastic leukemia (ALL) patients
  2. Fludarabine
    1. CLL and other leukemias, lymphomas
DNA Intercalating Agents
1. Anthracyclines
  1. Daunorubicin
    1. AML
  2. Doxorubicin
    1. Sarcomas, breast and lung carcinomas, malignant lymphomas
  3. Epirubicin
    1. Metastatic breast and gastric cancer
  4. Idarubicin
    1. AML
  5. Mitoxantrone
    1. AML, prostate cancer
  6. Bleomycin
    1. Squamous cell carcinomas and lymphomas
    2. Part of combo therapy for testicular tumors
Microtubule Inhibitors
1. Vinca Alkaloids
  1. Vinblastine
    1. Part of combo with bleomycin and cisplatin to treat metastatic breast cancer
    2. Part of ABVD
  2. Vincristine
    1. Childhood ALL, Hodgkin's and non-Hodgkin's lymphoma
2. Taxanes
  1. Paclitaxel
    1. Metastatic breast, ovarian, lung, and head and neck cancers (including glioblastomas)
  2. Docetaxel
    1. Metastatic breast, ovarian, lung, head and neck cancers (including glioblastomas), and hormone-refractory prostate cancer
Topoisomerase Inhibitors
1. Epipodophyllotoxins
  1. Etoposide
    1. Testicular and lung carcinomas, non-Hodgkin's lymphoma
2. Camptothecin Analogs
  1. Irinotecan
    1. Colorectal, lung, ovarian, cervical, and brain cancers
  2. Topotecan
    1. Ovarian and small cell lung cancers
Hormone Therapy
1. Glucocorticoids
  1. Prednisone
    1. Part of combo therapy for Hodgkin's lymphoma, NHL, multiple myeloma, and CLL
  2. Dexamethasone
    1. Reduces edema in brain and spinal tumors, in combination with radiation
2. Selective Estrogen-Receptor Modulators (SERMs)
  1. Tamoxifen
    1. ER-positive metastatic breast cancer
    2. Breast cancer prevention
3. Aromatase Inhibitors
  1. Exemestane
    1. ER-positive breast cancer in postmenopausal women
  2. Anastrozole
    1. ER-positive breast cancer in postmenopausal women
  3. Letrozole
    1. ER-positive breast cancer in postmenopausal women
4. GnRH Analogs
  1. Leuprolide
    1. Advanced prostate cancer, in combination with an AR blocker
  2. Goserelin
    1. Advanced prostate cancer, in combination with an AR blocker
5. Nonsteroidal Androgen-Receptor (AR) Blockers
  1. Flutamide
    1. Advanced prostate cancer, in combination with a GnRH analog
  2. Biclutamide
    1. Advanced prostate cancer, in combination with a GnRH analog
Targeted Small Molecules
1. Tyrosine Kinase Inhibitors
  1. Imatinib
    1. CML (first-line), ALL, gastrointestinal tumors
  2. Gefitinib
    1. Non-small cell lung cancer (NSCLC)
  3. Erlotinib
    1. NSCLC, pancreatic cancer
  4. Afatinib
    1. NSCLC
  5. Nilotinib
    1. Imatinib-resistant CML
  6. Dasantinib
    1. Imatinib-resistant CML
  7. Bosuntinib; Ponatinib
    1. Imintinib-resistant CML
  8. Lapatinib
    1. HER2+ metastatic breast cancer, menopausal women
  9. Crizotinib; Ceritinib
    1. ALK+ metastatic NSCLC
2. Serine/Threonine Kinase Inhibitors
  1. Vemurafenib
    1. BRAF+ metastatic, stage III/IV melanomas
  2. Dabrafenib
    1. BRAF+ metastatic, stage III/IV melanomas
3. Dual Specificity Kinase
  1. Tramentinib
    1. BRAF+ metastatic, stage III/IV melanomas
4. All-trans retinoic acid (ATRA)
  1. Acute promyelocytic leukemia (APL)
Immunotherapy
1. Monoclonal Antibodies
  1. Rituximab
    1. NHL
  2. Trastuzumab
    1. HER2+ metastatic breast cancer
  3. Pertuzumab
    1. Erb2+ metastaic breast cancer
2. Antibody-Drug Conjugate
  1. Ado-trastuzumab emtanasine
    1. HER2+ metastatic breast cancer, having failed prior treatment
3. Humanized Monoclonal Antibody
  1. Pembrolizumab
    1. Advanced NSCLC, head and neck squamous cell cancer, Hodgkin’s lymphoma
4. Human Monoclonal Antibody
  1. Ipilimumab
    1. Melanoma
  2. Nivolumab
    1. Melanoma with BRAF V600 mutation, metastatic squamous NSCLC
5. Cytokine
  1. Interleukin-2
    1. Malignant melanoma, renal cell cancer
Combination Therapy
1. ABVD
  1. Doxorubicin (Adriamycin), Bleomycin, Vinblastine, Dacarbazine
    1. Hodgkin's Lymphoma
2. CHOP
  1. Cyclophosphamide, Hydroxydoxorubicin, Vincristine (Oncovine), Prednisone
    1. Non-Hodgkin's Lymphoma
3. BEP
  1. Bleomycin, Etoposide, Cisplatin
    1. Testicular cancer
4. FOLFOX
  1. Leucovorin, Fluorouracil, Oxaliplatin
    1. Colorectal cancer
5. AC-T
  1. Doxorubicin (Adriamycin), Cyclophosphamide, Paclitaxel (Taxol)
    1. Breast cancer

Next up

Antineoplastic Agents

Description

Resource summary

Similar

	Created by Breanna Felldin over 6 years ago